CoChat
Sign Up
Cited by 634Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesNanoparticle-Based Drug Delivery

The DOI matches its Crossref record; 139 of the 142 references it cites were found in a registry or an index.

Improving cancer immunotherapy through nanotechnology

Goldberg, Michael S.·2019·Nature reviews. Cancer
DOI 10.1038/s41568-019-0186-9
Open this paper in CoChat — free account

Abstract

The 2018 Nobel Prize in Physiology or Medicine was awarded to pioneers in the field of cancer immunotherapy, as the utility of leveraging a patient's coordinated and adaptive immune system to fight the patient's unique tumour has now been validated robustly in the clinic. Still, the proportion of patients who respond to immunotherapy remains modest (~15% objective response rate across indications), as tumours have multiple means of immune evasion. The immune system is spatiotemporally controlled, so therapies that influence the immune system should be spatiotemporally controlled as well, in order to maximize the therapeutic index. Nanoparticles and biomaterials enable one to program the location, pharmacokinetics and co-delivery of immunomodulatory compounds, eliciting responses that cannot be achieved upon administration of such compounds in solution. The convergence of cancer immunotherapy, nanotechnology, bioengineering and drug delivery is opportune, as each of these fields has matured independently to the point that it can now be used to complement the others substantively and rationally, rather than modestly and empirically. As a result, unmet needs increasingly can be addressed with deductive intention. This Review explores how nanotechnology and related approaches are being applied to augmenting both endogenous leukocytes and adoptively transferred ones by informing specificity, influencing localization and improving function.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41568-019-0186-9

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 142 references

Research works printed but not linked: 2

  1. Luteijn, R. et al. SLC19A1 is a cyclic dinucleotide transporter. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/539767v1 (2019). · DOI
  2. Nature Collection: Nobel Prize in Physiology or Medicine 2018, https://www.nature.com/collections/gqznlfngkz (2018).

Cited by

Sorted by citations

Items 601–634 of 634

Related

See all

Metadata

Authors
Goldberg, M. S.
Affiliations
Massachusetts Institute of Technology (US)
Corresponding author
Goldberg, Michael S.
ORCID
Goldberg, Michael S.
Venue
Nature reviews. Cancer
Publisher
Springer Science and Business Media LLC
Published
2019-09-06
Volume
19
Issue
10
Pages
587-602
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
DOI
10.1038/s41568-019-0186-9
OpenAlex
W2972159813
Cited by
628
References
142
Citations by year
2026: 44 · 2025: 67 · 2024: 81 · 2023: 98 · 2022: 114 · 2021: 122 · 2020: 92 · 2019: 10
FWCI
8.06
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature reviews. Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
cancer immunotherapy, nanotechnology, nanoparticles, biomaterials, drug delivery, immune evasion, spatiotemporal control, pharmacokinetics, co-delivery, adoptive immunotherapy, tumor targeting, nanomedicine
MeSH terms
Animals, Biocompatible Materials, Humans, Immune System, Immunologic Factors, Immunotherapy, Leukocytes, Neoplasms, Nucleic Acids, T-Lymphocytes, Drug Delivery Systems, Adoptive Transfer, Nanomedicine, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review